Balloon aortic valve dilatation has been assumed by some to provide the same outcomes as surgical aortic valvuloplasty. However, the development of precise modern surgical valvuloplasty techniques may result in better
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
September 12, 2016
The presence of a bicuspid valve has been considered as a relative contraindication for transcatheter aortic valve implantation (TAVI). This a multicentre retrospective study of 51 patients with bicuspid aortic stenosis who had undergone TAVI using a next-generation transcatheter heart valve (Edwards SAPIEN 3). 30- day mortality was 3,9%.
September 7, 2016
This multistudy registry, entitled ROUTE, studied the effectiveness and safety of transaortic access for TAVI in 301 patients. Mean age was 82 years and mean STS Score 9.0. Valve success was 97%.
September 6, 2016
In this retrospective review of 460 consecutive patients undergoing transcatheter aortic valve implantation with the Edwards Sapiens XT or Sapiens 3 prosthesis, the authors analyse the incidence, clinical implications and predisposing factors related to trancatheter heart valve (THV) thrombosis.
August 9, 2016
In this study the investigators aimed to study whether a cerebral protection device during TAVI reduced the number of cerebral lesions in patients undergoing TAVI.
August 9, 2016
The following video shows an Edwards SAPIEN 3 TMVR implanted through the apical Certitude delivery system in a patient with severe mitral insufficiency following a bioprosthetic failure.
July 28, 2016
Filmed at the 2016 STS Annual Meeting in Phoenix, Arizona, a group of experts discuss the future of aortic stenosis treatment.
July 25, 2016
The authors describe their findings in a multicenter retrospective review of clinical outcomes in 64 patients with severe mitral annular calcification considered poor candidates for traditional surgical mitral valve replacement, undergoing transcatheter mitral valve implantation with a balloon expandable prosthesis.
July 14, 2016
This article explores the controversial topic of TAVR versus surgical AVR in low-risk patients. The primary outcome was 3-year survival. The authors report 3-year survival for TAVR and surgical AVR as 72% and 83.4%, respective (p=0.0015). Although TAVR is an exciting technology, there should be caution in adopting it in lower risk patients.
June 28, 2016
This article investigates the effects of varying degrees of aortic regurgitation (AR) on survival after transcatheter aortic valve replacement (TAVR). They retrospectively evaluated a cohort of 237 patients undergoing TAVR from 2006 to 2012 with echocardiogram performed within 30 days of the procedure. Using a Cox proportional multivariable regress